Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial

Go back to Resources

A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy

Go back to Resources

A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials

Go back to Resources

A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials

Authors:

Secondary:

Location:

URL:

Go back to Resources

2008 Update on Allogeneic Islet Transplantation from the Collaborative Islet Transplant Registry

Go back to Resources

2008 Update on Allogeneic Islet Transplantation from the Collaborative Islet Transplant Registry

Authors:

Secondary:

Volume:

Location:

URL:

Go back to Resources

2008 Update from the Collaborative Islet Transplant Registry

Go back to Resources

2008 Update from the Collaborative Islet Transplant Registry

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

The SCORE Study: Design and Baseline Characteristics

Go back to Resources

The SCORE Study: Design and Baseline Characteristics

Authors:

Secondary:

Location:

Go back to Resources

The Relationship of Dietary Omega-3 Long-Chain Polyunsaturated Fatty Acid Intake with Incident Age-Related Macular Degeneration: AREDS Report No. 23

Go back to Resources

The Relationship of Dietary Omega-3 Long-Chain Polyunsaturated Fatty Acid Intake with Incident Age-Related Macular Degeneration: AREDS Report No. 23

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project

Go back to Resources

The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Retention Strategies Used in a Large Multi-site Ophthalmic Trial

Go back to Resources

Retention Strategies Used in a Large Multi-site Ophthalmic Trial

Authors:

Secondary:

Location:

Go back to Resources

Recombinant Growth Hormone Use Pretransplant and Risk for Post-Transplant Lymphoproliferative Disease–a Report of the NAPRTCS

Go back to Resources

Recombinant Growth Hormone Use Pretransplant and Risk for Post-Transplant Lymphoproliferative Disease–a Report of the NAPRTCS

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 174
  • Page 175
  • Page 176
  • Page 177
  • Current page 178
  • Page 179
  • Page 180
  • Page 181
  • Page 182
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification